Skip to main content

Table 3 Post-index clinical characteristics in the treatment-naïve propensity score-matched cohorts - (rates per 1,000 patient-years)

From: Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort

  Total Febuxostat Allopurinol Allopurinol vs. febuxostat
(N = 1,746) (N = 873) (N = 873) Incidence rate ratio
(95% confidence interval)
Kidney failure 14.8 24.2 5.3 0.22 (0.08, 0.51)
Kidney stones 4.0 3.6 4.5 1.26 (0.32, 5.21)
Dialysis 7.4 7.9 6.8 0.85 (0.31, 2.27)
Angina 21.4 19.8 23.0 1.16 (0.67, 2.03)
Diabetes 76.0 85.6 66.4 0.78 (0.56, 1.08)
Coronary artery disease 80.1 75.1 85.3 1.13 (0.84, 1.53)
Heart failure 25.2 31.3 18.8 0.60 (0.35, 1.02)
Myocardial infarction 17.9 18.3 17.5 0.95 (0.52, 1.75)
Stroke 32.5 35.9 28.9 0.81 (0.51, 1.26)
Peripheral arterial disease 18.8 21.4 16.0 0.75 (0.40, 1.36)
Osteoarthritis 170.6 182.5 158.6 0.87 (0.70, 1.08)
Hypertension 231.0 234.4 227.5 0.97 (0.74, 1.27)
Hyperlipidemia 355.6 358.5 352.8 0.98 (0.80, 1.20)
Alcohol abuse 8.1 7.2 9.1 1.25 (0.50, 3.24)